367. Targeting VEGF in patients with colorectal liver metastasis prior to hepatectomy: Impact on peri-operative course

Abstract

Background: Neo-adjuvant treatment with Bevacizumab is often used in patients prior to hepatectomy for colorectal liver metastasis (CLRM). This is a retrospective study to investigate whether Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, can be associated with an increased rate of perioperative complications in patients undergoing hepatectomy for CLRM. Materials and methods: A retrospective analysis of patients undergoing liver resection for CRLM who received neo-adjuvant chemotherapy and bevacizumab (group 1, n 1⁄4 133), or chemotherapy alone (group 2, n 1⁄4 103). We compared demographics, surgical characteristics and perioperative course. Results: Perioperative complications were reported in 39.8% of patients in group 1 and 35.3% in group 2 (p 1⁄4 0.418). Of these complications, 20 (19.4%) in group 1 and 20 (15%) in group 2 were classified as major (Clavien 3,4) (p 1⁄4 0.523). The median time from the end of systemic treatment to the time of liver resection was 62 days (23e173 days) for the chemotherapy group and 66 days (35e147 days) for the chemotherapy and bevacizumab group). Conclusion: Neo-adjuvant chemotherapy along with bevacizumab was not associated with an increased risk of post-operative complications after hepatic resection. An interval of 8 weeks between the last dose of bevacizumab and liver resection appears to be safe for a surgical procedure without adverse effects on the clinical outcome. No conflict of interest.